Home › Steatotic Liver Disease › New York › Syracuse
Steatotic Liver Disease clinical trials in Syracuse, NY
3 studies for Steatotic Liver Disease are looking for participants at sites in and around Syracuse (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
RecruitingPhase 3
- GSK Investigational Site, East Syracuse · 4 mi away
A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
RecruitingPhase 3
- GSK Investigational Site, East Syracuse · 4 mi away
A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
RecruitingPhase 3
- GSK Investigational Site, East Syracuse · 4 mi away
About Steatotic Liver Disease
Steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in your liver. Learn about the causes and treatments.
More about Steatotic Liver Disease on MedlinePlus
Steatotic Liver Disease trials in other cities
- Miami, FL17 studies
- San Antonio, TX16 studies
- New York City, NY16 studies
- Houston, TX14 studies
- Austin, TX13 studies
- San Diego, CA12 studies
- Hialeah, FL11 studies
- Richmond, VA11 studies
- New Orleans, LA10 studies
- Orlando, FL10 studies
- Tucson, AZ10 studies
- Cape Coral, FL9 studies
Other studies in Syracuse
- Non-Small Cell Lung Cancer16 studies
- Cancer (all types)9 studies
- Prostate Cancer9 studies
- Non-Muscle Invasive Bladder Cancer9 studies
- Ovarian Cancer7 studies
- Endometrial Cancer7 studies
- Colorectal Cancer6 studies
- Acute Myeloid Leukemia6 studies
- Type 2 Diabetes6 studies
- Obesity6 studies
- Lung Cancer6 studies
- Breast Cancer5 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.